

Tata Consumer Products

BSE SENSEX

72,639

S&P CNX

22,603



TATA CONSUMER PRODUCTS LIMITED

Bloomberg	TATACONS IN
Equity Shares (m)	990
M.Cap.(INRb)/(USD\$)	958.5 / 9.9
52-Week Range (INR)	1283 / 945
1, 6, 12 Rel. Per (%)	0/-6/-4
12M Avg Val (INR M)	1793
Free float (%)	66.0

Financials Snapshot (INR b)

Y/E MARCH	2025	2026E	2027E
Sales	203	225	244
EBITDA	28	33	37
Adj. PAT	16	19	22
EBITDA Margin (%)	14	15	15
Cons. Adj. EPS (INR)	16	19	23
EPS Gr. (%)	21	21	19
BV/Sh. (INR)	236	250	268

Ratios

Net D:E	0	0	0
RoE (%)	7	8	9
RoCE (%)	9	10	12
Payout (%)	42	34	29

Valuations


P/E (x)	63	52	44
EV/EBITDA (x)	32	27	23
Div. Yield (%)	1	1	1
FCF Yield (%)	2	2	2

Shareholding pattern (%)

As On	Jun-26	Mar-26	Jun-25
Promoter	33.8	33.8	33.8
DII	25.0	24.2	22.0
FII	20.1	20.8	22.0
Others	21.1	21.2	22.2

FII Includes depository receipts

Stock's performance (one-year)



CMP: INR969

TP: INR1,230 (+27%)

Buy

Tea remains resilient; growth portfolio scales up as next growth engine

After 5% YoY growth in FY26, India's tea production declined 1% YoY in Jan-Aug'26 due to adverse weather conditions in Assam and West Bengal. Tea prices peaked in Jun'26 but declined by 8%/3% MoM in Jul/Aug'26, owing to the normalization of regulations imposed on Nepalese tea imports and higher production in Jun'26 (up 14% YoY). The Indian tea business of Tata Consumer Products (TATACONS) is expected to remain resilient, with the company implementing pricing actions to partly offset the cost pressure. Moreover, the company continues to expand its growth portfolio with launches across segments. The growth portfolio is emerging as the next key growth driver, gradually reducing the company's dependence on its core tea business while reshaping the product mix and tapping into new and large market opportunities.

Tea production outlook resilient despite weather disruptions

- In the FY26 tea season, domestic production grew 5% YoY to 1,383m kg, led by ~6% and ~2% growth in North and South India, respectively.
- **Tea production for the current season YTD (Jan-Aug'26)** has declined 1% YoY to 840.2m kg, caused by the severe heatwave and drought conditions attributed to El Nino. Production in South India has declined by 4% YoY, while production in North India has been flat.
- All India tea production rose 2% YoY during the first flush (*Feb-Jun'26, contributed 34% to the total tea cycle volume in CY25 and generally has the best quality*), fueled by strong 14% YoY production growth in Jun'26.
- July is usually the start of the second flush (*Jul-Sep, contributed 37% to the total volume in CY25 and has the second-best quality*). In Jul'26, all India tea production declined 10% YoY to 164.33m kg, as growth in South India (up 18% YoY) was offset by decline in North India (down 14% YoY).
- Heavy rainfall in Jul'26 flooded tea gardens in Assam and West Bengal, making plucking of tea leaves difficult for workers. As a result, production in Assam fell 13% YoY to 91.08m kg in Jul'26, and production in West Bengal declined 14% YoY to 43.87m kg.
- Production grew 4% YoY in Aug'26, supported by a recovery in North India (+4%) and South India (+3%), while West Bengal was the key growth driver with a 15% YoY increase.
- Going ahead, we expect tea production to remain flat in FY27 despite flood-related disruptions in Assam and West Bengal, alongside the adverse impact of El Niño on tea-growing conditions.

Research Analyst: Sumant Kumar (Sumant.Kumar@MotilalOswal.com) | Nirvik Saini (Nirvik.Saini@MotilalOswal.com) |

Research Analyst: Swapnil Upadhyay (Swapnil.Upadhyay@MotilalOswal.com) | Yash Darak (Yash.darak@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

Tea prices remain firm; calibrated pricing to protect margins

- In FY26, TATACONS' tea business displayed resilience amid inflationary pressure. The company navigated a volatile commodity pricing environment by calibrating pricing actions and implementing targeted market interventions to ensure growth.
- Despite a 14% YoY increase in Indian tea production to 160.4m kg in Jun'26, tea prices remained firm, peaking at INR233/kg during the month. Tea prices were supported by tighter quality and testing requirements for imported tea, which disrupted Nepalese tea supplies to India, as shipments were reportedly suspended between 1st May and 30th Jun'26.
- However, normalization of these regulations after Jun'26 led to prices declining by 8%/3% MoM in Jul'26/Aug'26 to average INR214/INR206 per kg. Despite the sequential correction, prices remained higher compared to last year.
- TATACONS subsequently implemented a price increase in Jun'26 to partially offset the rise in input costs. As per our channel checks, the company has further implemented a 3-5% price hike in the middle of 2QFY27.
- Going ahead, the company remains committed to protecting margins through calibrated cost pass-through while balancing volume growth and consumer affordability.
- We expect margin to normalize, supported strong production and the stabilization of tea prices.

Growth portfolio scaling up rapidly, paving the way for lower dependence on tea business

- TATACONS' growth portfolio has scaled up significantly, increasing its contribution to India business from ~8% in FY21 to ~31% in FY26, driven by the rapid expansion of Tata Sampann, Tata Soufull, Capital Foods, Organic India and RTD beverages. In contrast, the tea business' contribution declined from ~38%/63% in FY21 to ~24%/39% of the Consolidated/India Business in FY26, highlighting the company's growing diversification beyond its core tea franchise.
- The portfolio has expanded across multiple high-growth categories, broadening TATACONS' presence beyond its traditional tea-led business.
- The growth portfolio is expected to emerge as the next key growth driver, gradually reducing the company's dependence on its core tea business while reshaping the product mix and tapping into new and large market opportunities.
- In FY26, the growth business crossed the milestone of INR40b, growing 24% YoY. In 1QFY27, the growth business grew 47% YoY, led by Tata Sampan (up 58%), RTD revenue (up 41%), Capital Food (up 40%) and Organic food (up 27%).
- Tata Sampann continues to expand into adjacent categories, with launches across gravy masalas, unpolished millets, protein-led snacks and whole spices, broadening its portfolio and addressable market from pantry staple products like pulses.
- The RTD segment is expanding through launches in electrolytes, cold coffee, energy, flavored beverages and kombucha from its current portfolio of sports hydration and electrolytes. Affordable INR10-20 price points and master brands such as Tetley and Tata Coffee support mass adoption. Copper Plus grew 26% in FY26, validating the functional-water opportunity.

- Organic India has expanded beyond its traditional herbal teas and organic foods into supplements and nutraceuticals with new Organic India “Advance” formulations, strengthening its presence in herbal supplements.
- Capital Foods has evolved from being a primarily Chinese sauce brand into a broader convenience-food platform spanning Ching’s Secret and Smith & Jones, with products across sauces, chutneys, soups, instant noodles, masalas, cooking aids and other convenience categories.
- The company continues to drive growth through an aggressive innovation pipeline, with significantly higher innovation-to-sales ratios for Tata Sampann (19.6%) and Tata Soulfull (20.1%) vs. the company average of 4.5% in FY26.
- Further, TATACONS is strengthening its transformation into a diversified F&B platform through a comprehensive GTM overhaul, focused on improving distribution productivity and accelerating penetration of its growth portfolio.

Valuation and view


- With the moderation in tea prices from its peak and strategic price hikes in the tea business, we expect TATACONS’ standalone gross margins to remain resilient in FY27.
- The company is expected to sustain its growth momentum, aided by the mid-to-long-term triggers such as 1) strengthening and accelerating its growth business, 2) expanding its product portfolio and innovation, 3) enhancing its focus on premiumization and health and wellness products, and 4) higher innovation-to-sales ratio.
- **We expect TATACONS to clock a CAGR of 10%/15%/20% in revenue/EBITDA/PAT during FY26-28. Reiterate BUY with an SoTP-based TP of INR1,230.**

Exhibit 1: SoTP valuation

EV/EBITDA	FY28 EBITDA	Multiple (x)	EV
India Branded Business	30,879	33	10,29,587
International Branded Business	7,478	10	74,775
Non-branded Business	1,671	10	16,711
Elimination	-2,827	10	-28,270
DCF			
Starbucks JV			74,719
Enterprise value			11,67,522
Less: Net debt			(49,686)
Market value (INR m)			12,17,208
No. of shares (m)			990
Target price (INR)			1,230


Source: MOFSL

Exhibit 2: One-year forward P/E ratio (x)




Source: MOFSL

Exhibit 3: Standalone gross margin trend




Source: MOFSL

Exhibit 4: Region-wise tea production in India




Source: Tea Board of India, MOFSL

Exhibit 5: State-wise production mix (Jan-Jul'26, M.Kgs/%)




Source: Tea Board of India, MOFSL

Exhibit 6: Domestic trend in tea production




Source: Tea Board of India, MOFSL

Exhibit 7: Tea production in CY26 (YTD) has been marginally lower than the previous levels




Source: Tea Board of India, MOFSL

Exhibit 8: Annual tea production trend in India



Source: Tea Board of India, MOSFL


Exhibit 9: Tea prices in India (INR/kg)



*Provisional, subject to revision

Source: Tea Board of India, MOFSL


Exhibit 10: Tea prices in North India (INR/kg)



*Provisional, subject to revision

Source: Tea Board of India, MOFSL

Exhibit 11: Tea prices in South India (INR/kg)



*Provisional, subject to revision

Source: Tea Board of India, MOFSL

Exhibit 12: All India weekly CTC prices




Exhibit 13: Growth in tea volumes for TATACONS




Exhibit 14: Tea realization and growth trends for TATACONS




Exhibit 15: New product launches over the years







Exhibit 16: Mix of key products launched over the years



Source: Company, MOFSL

Exhibit 17: Share of growth business rising over the years

Exhibit 18: Innovation-to-sales ratio across the years


Source: Company, MOFSL

Exhibit 19: Key product launches from FY22 to FY26

Segment	Key brands	FY22	FY23	FY24	FY25	FY26
Core						
India beverages	Tata coffee					Vietnamese Ca Phe
	Tata coffee grand					Irish cream
	Tata Tea	Chakra gold care	Hyderabadi Irani chai	Instant liquid tea premix (Lemon honey flavour)	Instant premix Cardamom Flavour	Instant iced tea (Peach flavour)
		1868 (Cinnamon clove)	Mumbai cutting chai	Instant liquid tea premix (Kashmiri Kahwa flavour)	Instant premix Masala Flavour	Instant iced tea (Lemon flavour)
		Agni	Kolkata street chai			
India foods	Tata salt	low sodium iodised salt	Tata Salt Immuno- Salt fortified with Iodine and Zinc		Rock salt + Iodised Salt	LoSodium Rock salt
		Shuddh	Tata Salt Iron Health- Salt fortified with iodine and iron		Iron health	
			Vitamin Shakti, fortified with Vitamin D and calcium			
			Pink salt			
International	Tetley		Immune TulsiFortified with Vitamin C	Immuno Chai		Matcha latte (Mango)
				Digest Chai		Matcha latte (Classic)
						Matcha latte (Vanilla)
Growth						
India beverages						
	Tata Gluco +	Jelly energy drink (Mango)			Berry blast	Tata electrolyte
		Jelly energy drink (Orange)			Green apple punch	
		Jelly energy drink (Strawberry)				
	Himalayan			Kashmiri saffron		Kedar honey
	Tata coffee	Gold		Classic		Caramel Flavour
		Dark Roast		Cold brew (Hazelnut flavour)		Hazelnut Flavour
				Sonnets		
				Quick Filter		
	Organic India				Desi khandsari sugar	Revitalise Throat
					Gokshura	Revitalise Gut

Segment	Key brands	FY22	FY23	FY24	FY25	FY26
						Revitalise Sleep
	Tata Lyfe+				Alkaline ph 8+	
	Say never			Energy drink		
	Tata spring alive			spring alive		
	Tata gofit		Tata GoFitPlant Protein powder	Apple cider vinegar		
India foods	Tata Soulfull	Millets muesli	Masala Oats+ Oats with 25% millets	Ragi bites (Choco Sticks)	Ragi bites (Orange Sticks)	Ultimate millet muesli Hi - Protein
		Millets smoothix	Ragi bites (Cream fills)			Ultimate millet muesli Probiotic
			Ragi bites (Strawberry fills)			
	Smith & Jones				Pink pasta sauce mix	Chilli ginger garlic paste
					White pasta sauce mix	Masala Noodles
					Crunchy fried chicken mix	
	Simply better		Plant based meat	Keema		Avocado Oil
				Biryani		
				Chucks		
	Tata Sampann			Burger patty		
		Manchurian rice masala	Dry Fruits and Nuts Mix	Classic Mac & cheese	Inshell walnut	
		California almonds	Cheesy pasta	Sunflower seeds	Chatpati Dhaniya pudina chutney Dip	
			Makhani gravy	Pupmkin seeds	Theekhi Imli Saunth Chutney Dip	
			Hing	flax seed	Meethi Imli Khajur Chutney Dip	
			High protein makhana	Walnut		
			Poha indori style	Oats + Millet granola		
	Chings Secret				Momo chutney	
					Pizza and pasta sauce	
					Schezwan Instant Noodles	
					Manchurian Instant Noodles	
					Whole wheat Noodles	
	Joyfull Millets			Honey & Nut Crunchy Muesli		
	Tata Raasa		Kashmiri rogan josh Delhi dal makhni			
International	Good earth	Tropical mango				
		Rodibos chai				
		Kombucha Original				
		Good energy (Organic Guayusa)				
	Teapigs	Blackcurrant & Raspberry				
		Pink grapefruit				
		Watermelon & Hibiscus				
		Cucumber & Apple tea				
		Lychee & Rose tea				
		Peach & Mango Tea				
Kombucha						
Total products launched		25	34	46	41	80

Source: Company, MOFSL

Financials and valuations

Consolidated Income Statement							(INRm)	
Y/E March	2021	2022	2023	2024	2025	2026	2027E	2028E
Net Sales	1,16,020	1,24,254	1,37,832	1,54,260	1,76,183	2,02,904	2,24,922	2,44,194
Change (%)	20.4	7.1	10.9	11.9	14.2	15.2	10.9	8.6
Gross Profit	46,997	53,414	57,775	65,745	75,490	84,348	96,089	1,05,575
Margin (%)	40.5	43.0	41.9	42.6	42.8	41.6	42.7	43.2
Other operating exp.	31,560	36,226	39,210	43,274	50,697	56,430	63,223	68,374
EBITDA	15,438	17,188	18,565	22,470	24,794	27,918	32,866	37,201
Margin (%)	13.3	13.8	13.5	14.6	14.1	13.8	14.6	15.2
Depreciation	2,547	2,780	3,041	3,691	6,007	6,267	7,126	7,150
Net Interest	687	728	872	1,298	2,902	1,370	1,484	1,484
Other income	1,214	1,401	1,689	2,456	1,933	1,648	2,046	2,168
PBT before EO	13,417	15,081	16,341	19,938	17,817	21,928	26,301	30,735
EO income/(exp.)	-307	-521	1,595	-3,270	-51	-201	0	0
PBT after EO	13,111	14,560	17,936	16,667	17,766	21,728	26,301	30,735
Tax	3,173	3,770	4,470	3,947	3,962	5,353	6,605	7,736
Rate (%)	24.2	25.9	24.9	23.7	22.3	24.6	25.1	25.2
Minority and Associates	1,371	1,432	1,428	1,507	1,018	952	920	629
Reported PAT	8,567	9,358	12,038	11,213	12,785	15,423	18,776	22,369
Adjusted PAT	8,797	9,748	10,842	13,666	12,823	15,573	18,776	22,369
Change (%)	21.9	10.8	11.2	26.1	-6.2	21.4	20.6	19.1

Balance Sheet							(INRm)	
Y/E March	2021	2022	2023	2024	2025	2026	2027E	2028E
Share Capital	922	922	929	953	990	990	990	990
Reserves	1,44,424	1,50,498	1,61,838	1,59,615	1,99,021	2,16,886	2,29,441	2,45,589
Net Worth	1,45,345	1,51,419	1,62,767	1,60,568	2,00,011	2,17,875	2,30,430	2,46,578
Minority Interest	10,925	11,516	8,502	13,793	13,892	14,013	14,091	14,091
Loans	12,066	10,106	11,828	29,539	18,487	21,203	21,203	21,203
Capital Employed	1,68,337	1,73,042	1,83,097	2,03,900	2,32,390	2,53,092	2,65,725	2,81,873
Gross Block	61,773	66,671	71,650	1,13,913	1,31,132	1,35,887	1,39,887	1,43,887
Less: Accum. Deprn.	21,371	24,151	27,192	30,883	36,890	43,157	50,283	57,433
Net Fixed Assets	40,402	42,520	44,458	83,030	94,242	92,730	89,604	86,454
Capital WIP	1,129	4,618	5,097	4,044	4,317	6,948	6,948	6,948
Goodwill & Intangibles	75,966	77,541	80,254	1,03,343	1,13,304	1,18,839	1,18,839	1,18,839
Investments	4,827	5,993	6,782	6,319	6,765	5,744	4,902	4,273
Curr. Assets	79,855	80,077	91,034	82,052	99,679	1,18,526	1,40,602	1,65,372
Inventories	22,492	22,665	27,017	27,694	35,999	35,268	44,368	48,170
Account Receivables	7,613	8,352	7,983	8,968	8,698	11,483	13,557	14,719
Cash and Bank Balance	33,980	27,979	35,517	26,931	31,101	42,887	52,468	70,889
Others	15,770	21,082	20,517	18,460	23,881	28,889	30,209	31,595
Curr. Liability & Prov.	28,372	30,235	36,384	58,358	65,514	69,444	74,918	79,761
Account Payables	16,255	19,159	23,482	27,072	35,084	38,753	43,136	46,832
Other liabilities	9,175	8,589	10,453	27,399	26,878	26,663	27,647	28,680
Provisions	2,942	2,488	2,449	3,887	3,551	4,027	4,135	4,249
Net Curr. Assets	51,484	49,842	54,650	23,695	34,165	49,083	65,684	85,612
Def. tax liability	5,470	7,472	8,144	16,531	20,403	20,252	20,252	20,252
Appl. of Funds	1,68,337	1,73,042	1,83,097	2,03,900	2,32,390	2,53,092	2,65,725	2,81,873

Financials and valuations

Ratios

Y/E March	2021	2022	2023	2024	2025	2026	2027E	2028E
Basic (INR)								
EPS	9.2	10.2	11.4	14.3	13.0	15.7	19.0	22.6
Cash EPS	11.5	12.7	14.0	17.5	19.0	23.7	28.1	32.0
BV/Share	146.9	153.0	164.5	162.3	202.1	236.4	250.0	267.6
DPS	4.1	6.1	6.1	6.5	6.5	6.5	6.5	6.5
Payout (%)	43.6	59.6	46.7	55.2	50.3	41.7	34.3	28.8
Dividend yield (%)	0.4	0.6	0.6	0.7	0.7	0.7	0.7	0.7
Valuation (x)								
P/E	106.8	96.4	86.7	68.7	76.1	62.7	52.0	43.6
Cash P/E	86.0	77.9	70.3	56.2	51.8	41.6	35.1	30.8
P/BV	6.7	6.4	6.0	6.1	4.9	4.2	3.9	3.7
EV/Sales	7.6	7.2	6.4	5.9	5.1	4.4	3.9	3.5
EV/EBITDA	57.4	51.8	47.7	40.6	36.1	31.8	26.7	23.1
Dividend Yield (%)	0.4	0.6	0.6	0.7	0.7	0.7	0.7	0.7
FCF per share	15.7	13.5	12.4	16.8	16.1	19.9	15.6	24.4
Return Ratios (%)								
RoE	6.2	6.6	6.9	8.5	7.1	7.5	8.4	9.4
RoCE	8.2	8.9	9.5	10.5	9.1	9.2	10.4	11.5
RoIC	10.9	10.5	11.2	12.1	10.5	11.1	12.6	14.7
Working Capital Ratios								
Fixed Asset Turnover (x)	2.9	2.9	3.1	1.9	1.9	2.2	2.5	2.8
Asset Turnover (x)	0.7	0.7	0.8	0.8	0.8	0.8	0.8	0.9
Debtor (Days)	24	25	21	21	18	21	22	22
Creditor (Days)	51	56	62	64	73	70	70	70
Inventory (Days)	71	67	72	66	75	63	72	72
Leverage Ratio (x)								
Net Debt/Equity	-0.2	-0.1	-0.1	0.0	-0.1	-0.1	-0.1	-0.2

Cash flow statement

Y/E March	2021	2022	2023	2024	2025	2026	2027E	2028E
(INRm)								
EBITDA	15,438	17,188	18,565	22,470	24,794	27,918	32,866	37,201
Prov. & FX	41	7	4	123	0	0	0	0
WC	3,054	1,992	340	1,929	-23	1,817	-6,809	-1,296
Others	1,203	-258	175	-1,208	-241	-164	0	0
Direct taxes (net)	-3,173	-3,770	-4,470	-3,947	-3,962	-5,353	-6,605	-7,736
CF from Op. Activity	16,564	15,158	14,613	19,367	20,567	24,219	19,452	28,169
Capex	-2,107	-2,733	-3,118	-3,347	-4,595	-4,486	-4,000	-4,000
FCFF	14,457	12,425	11,495	16,020	15,971	19,733	15,452	24,169
Interest/dividend	731	881	1,214	1,906	1,180	1,063	2,046	2,168
Investments in subs/assoc.	-2,241	-7,362	-1,957	-38,844	-19,340	0	0	0
Others	-467	-4,004	-4,417	20,976	-781	-10,559	0	0
CF from Inv. Activity	-4,084	-13,218	-8,278	-19,309	-23,536	-13,982	-1,954	-1,832
Share capital	0	0	0	0	0	0	0	0
Borrowings	-573	-4,947	-38	12,540	-11,602	-641	0	0
Finance cost	-654	-625	-817	-1,183	-2,606	-1,115	-1,484	-1,484
Dividend	-2,673	-3,982	-5,734	-8,089	-7,415	-8,203	-6,432	-6,432
Others	851	1,613	7,791	-11,912	28,762	11,509	0	0
CF from Fin. Activity	-3,049	-7,941	1,203	-8,643	7,139	1,549	-7,917	-7,917
(Inc)/Dec in Cash	9,430	-6,001	7,538	-8,586	4,170	11,786	9,581	18,421
Opening balance	24,550	33,980	27,979	35,517	26,931	31,101	42,887	52,468
Closing balance (as per B/S)	33,980	27,979	35,517	26,931	31,101	42,887	52,468	70,889

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://online.reports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/Publish/ViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered/qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
- MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal,

Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.